Capricor Therapeutics Inc... (CAPR)

NEW YORK--(BUSINESS WIRE)---- $CAPR #CAPR--The law firm of Kirby McInerney LLP reminds investors who purchased Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ:CAPR) securities to con...

In May, FDA Commissioner Marty Makary named Vinay Prasad the next director of the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER). Within three months, Pr...

LOS ANGELES--(BUSINESS WIRE)---- $CAPR--Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR.

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Capricor Therapeutics, ...

OAKLAND, Calif.--(BUSINESS WIRE)---- $CAPR #CAPR--Gibbs Mura announces that a class action lawsuit has been filed on behalf of Capricor Therapeutics, Inc. (CAPR) investors.

LOS ANGELES--(BUSINESS WIRE)---- $CAPR--CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.

Capricor slumps 33% as the FDA rejects its BLA for DMD drug, deramiocel, citing lack of effectiveness data and CMC issues.

Capricor Therapeutics's dip caused by the Complete Response Letter is a buying opportunity considering the readout of HOPE-3 within 2-3 months. Based on HOPE-2 data and the expected course of Duchenne...

OAKLAND, Calif.--(BUSINESS WIRE)---- $CAPR #CAPR--Shares of Capricor Therapeutics, Inc. plunged over 30% in intraday trading on Friday, July 11, 2025, after the U.S. Food and Drug Administration rejec...

Capricor Therapeutics (NASDAQ:CAPR) shares plummeted more than 26% after it reported the US Food and Drug Administration (FDA) has not approved its Biologics License Application for deramiocel, the co...